-
公开(公告)号:US20250011756A1
公开(公告)日:2025-01-09
申请号:US18663845
申请日:2024-05-14
Applicant: Scribe Therapeutics Inc.
Inventor: Gayathri VIJAYAKUMAR , Sean HIGGINS , Isabel COLIN , Sarah DENNY , Brett T. STAAHL , Benjamin OAKES , Angus SIDORE , Suraj MAKHIJA
Abstract: Provided herein are engineered Class 2, Type V nucleases and guide RNAs useful for the editing of target nucleic acids. Also provided are methods of making and using such variants to modify nucleic acids.
-
公开(公告)号:US20240360474A1
公开(公告)日:2024-10-31
申请号:US18608127
申请日:2024-03-18
Applicant: Scribe Therapeutics Inc.
Inventor: Katherine BANEY , Isabel COLIN , Cécile FORTUNY , Sean HIGGINS , Suraj MAKHIJA , Brett T. STAAHL , Maroof ADIL , Benjamin OAKES , Addison WRIGHT , Angus SIDORE , Manuel MOHR , Sarah DENNY
CPC classification number: C12N15/86 , C12N9/22 , C12N15/111 , C07K2319/09 , C12N2310/14 , C12N2310/20 , C12N2310/531 , C12N2750/14122 , C12N2750/14123 , C12N2750/14143 , C12N2750/14152
Abstract: Provided herein are compositions and methods for use of self-inactivating recombinant vectors (SIRV) encoding Class 2 Type V and guide ribonucleic acid (gRNA) sequences useful for nucleic acid sequence editing, and including self-inactivating components. The SIRV may be delivered to cells as part of an AAV vector to target a gene of interest.
-
公开(公告)号:US20240254466A1
公开(公告)日:2024-08-01
申请号:US18612882
申请日:2024-03-21
Applicant: Scribe Therapeutics Inc.
Inventor: Jason FERNANDES , Ross WHITE , Sean HIGGINS , Sarah DENNY , Benjamin OAKES , Emeric Jean Marius CHARLES
CPC classification number: C12N9/22 , C12N15/11 , C12N15/88 , C12N2310/20
Abstract: The disclosure relates to gene repressor systems comprising catalytically-dead Class 2 CRISPR proteins and one or more transcription repressor domains linked to the catalytically-dead Class 2 CRISPR protein as a fusion protein, as well as a guide ribonucleic acid (gRNA); and methods of making and using same.
-
公开(公告)号:US20230183691A1
公开(公告)日:2023-06-15
申请号:US18164138
申请日:2023-02-03
Applicant: Scribe Therapeutics Inc.
Inventor: Jason FERNANDES , Sean HIGGINS , Isabel COLIN , Hannah SPINNER , Matthew GARDNER , Trent GOMBERG , Gayathri VIJAYAKUMAR , Sarah DENNY , Brett T. STAAHL , Maroof ADIL , Benjamin OAKES , Angus SIDORE , Suraj MAKHIJA
IPC: C12N15/11 , A61K9/00 , A61K9/50 , C07K14/005 , C12N9/22
CPC classification number: C12N15/111 , A61K9/0019 , A61K9/5052 , C07K14/005 , C12N9/22 , C12N2310/16 , C12N2310/20 , C12N2310/3519 , C12N2320/32
Abstract: Provided herein are delivery particle systems (XDP) useful for the delivery of payloads of any type. In some embodiments, a XDP particle system with tropism for target cells of interest is used to deliver CRISPR/Cas polypeptides (e.g., CasX proteins) and guide nucleic acids (gNA), for the modification of nucleic acids in target cells. Also provided are methods of making and using such XDP to modify the nucleic acids in such cells.
-
公开(公告)号:US20220348925A1
公开(公告)日:2022-11-03
申请号:US17641426
申请日:2020-09-09
Applicant: Scribe Therapeutics Inc.
Inventor: Benjamin OAKES , Sean HIGGINS , Hannah SPINNER , Sarah DENNY , Brett T. STAAHL , Kian TAYLOR , Katherine BANEY , Isabel COLIN , Maroof ADIL , Cole URNES
IPC: C12N15/113 , C12N15/10 , C12N9/22 , C12N9/06 , A61P25/28
Abstract: Provided herein are CasX:gNA systems comprising CasX polypeptides, guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a SOD1 gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the SOD1 protein or the SOD1 regulatory element. Also provided are methods of using such CasX:gNA systems to modify cells having such mutations and utility in methods of treatment of a subject with a SOD1-related disease.
-
公开(公告)号:US20220090036A1
公开(公告)日:2022-03-24
申请号:US17483692
申请日:2021-09-23
Applicant: Scribe Therapeutics Inc.
Inventor: Benjamin OAKES , Sean HIGGINS , Hannah SPINNER , Sarah DENNY , Brett T. STAAHL , Kian TAYLOR , Katherine BANEY , Isabel COLIN , Maroof ADIL , Cole URNES
Abstract: Provided herein are CasX:gNA systems comprising CasX polypeptides, guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a SOD1 gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the SOD1 protein or the SOD1 regulatory element. Also provided are methods of using such CasX:gNA systems to modify cells having such mutations and utility in methods of treatment of a subject with a SOD1-related disease.
-
公开(公告)号:US20220081681A1
公开(公告)日:2022-03-17
申请号:US17533997
申请日:2021-11-23
Applicant: Scribe Therapeutics Inc.
Inventor: Benjamin OAKES , Sean HIGGINS , Hannah SPINNER , Sarah DENNY , Brett T. STAAHL , Kian TAYLOR , Katherine BANEY , Isabel COLIN , Maroof ADIL
Abstract: Provided herein are engineered proteins. In some embodiments, the engineered proteins comprise a RuvC DNA cleavage domain comprising one or more modifications, relative to a naturally occurring domain. In some embodiments, the engineered proteins comprise a chimeric domain, for example a chimeric helical I domain. In some embodiments, the engineered proteins are chimeric proteins, comprising at least two domains, each domain derived from a different source, for example derived from SEQ ID NO: 1 and SEQ ID NO: 2. Also provided are systems comprising these engineered proteins, and methods of making and using said engineered proteins.
-
-
-
-
-
-